Business Description
ALX Oncology Holdings Inc
NAICS : 541714
SIC : 2834
ISIN : US00166B1052
Share Class Description:
ALXO: Ordinary SharesTotal Employee Number:
43Description
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 19.87 | |||||
Equity-to-Asset | -4.15 | |||||
Debt-to-Equity | -0.01 | |||||
Debt-to-EBITDA | -0.1 | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 15 | |||||
3-Year EPS without NRI Growth Rate | 15.3 | |||||
3-Year FCF Growth Rate | 11 | |||||
3-Year Book Growth Rate | -58 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 28.86 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 78.52 | |||||
9-Day RSI | 72.58 | |||||
14-Day RSI | 66.9 | |||||
3-1 Month Momentum % | -21.43 | |||||
6-1 Month Momentum % | 42.59 | |||||
12-1 Month Momentum % | 234.71 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 7.21 | |||||
Quick Ratio | 7.21 | |||||
Cash Ratio | 8.38 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -10 | |||||
Shareholder Yield % | -50.7 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROA % | -82.85 | |||||
ROIC % | -331.54 | |||||
3-Year ROIIC % | -126.24 | |||||
ROC (Joel Greenblatt) % | -1699.37 | |||||
ROCE % | -102.45 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 4 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
EV-to-EBIT | -2.13 | |||||
EV-to-EBITDA | -2.14 | |||||
EV-to-Forward-Revenue | 112.73 | |||||
EV-to-FCF | -2.37 | |||||
| Price-to-Net-Current-Asset-Value | 2.68 | |||||
| Price-to-Net-Cash | 2.23 | |||||
Earnings Yield (Greenblatt) % | -46.95 | |||||
FCF Yield % | -24.67 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ALXO
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
ALX Oncology Holdings Inc Executives
DetailsGF Value™
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -1.49 | ||
| Beta | 0.2635 | ||
| 3-Year Sharpe Ratio | 0.16 | ||
| 3-Year Sortino Ratio | 0.3 | ||
| Volatility % | 131.69 | ||
| 14-Day RSI | 66.9 | ||
| 14-Day ATR ($) | 0.161945 | ||
| 20-Day SMA ($) | 1.73825 | ||
| 12-1 Month Momentum % | 234.71 | ||
| 52-Week Range ($) | 0.4399 - 2.66 | ||
| Shares Outstanding (Mil) | 134.56 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
ALX Oncology Holdings Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
ALX Oncology Holdings Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-06 08:30 | In 123 days | ||
| Third quarter earnings results for 2026 | 2026-11-06 | In 122 days | ||
| Second quarter earnings results for 2026 | 2026-08-05 | In 29 days | ||
| General meeting for 2026 | 2026-06-10 13:00 | 1.55 (-1.90%) | ||
| Jefferies Global Healthcare Conference | 2026-06-03 17:30 | 1.78 (+1.14%) | ||
| First quarter earnings conference call for 2026 | 2026-05-08 08:30 | 1.87 (-10.53%) | ||
| First quarter earnings results for 2026 | 2026-05-08 | 1.87 (-10.53%) | ||
| Annual report for 2025 | 2026-03-09 | 2.21 (+2.31%) | ||
| TD Cowen 46th Annual Health Care Conference | 2026-03-03 09:10 | 2.12 (+4.95%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-02-27 08:30 | 2.35 (-2.89%) |
Show
Entries
ALX Oncology Holdings Inc Frequently Asked Questions
What is ALX Oncology Holdings Inc(ALXO)'s stock price today?
The current price of ALXO is $2.36. The 52 week high of ALXO is $2.66 and 52 week low is $0.44.
When is next earnings date of ALX Oncology Holdings Inc(ALXO)?
The next earnings date of ALX Oncology Holdings Inc(ALXO) is 2026-08-05 Est..
Does ALX Oncology Holdings Inc(ALXO) pay dividends? If so, how much?
ALX Oncology Holdings Inc(ALXO) does not pay dividend.
Guru Commentaries on NAS:ALXO
No articles.
Press Release
Articles on ALX Oncology Holdings Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers